WASHINGTON, DC (June 26, 2019) —The Association for Accessible Medicines (AAM) has announced the approval of Greenstone LLC, a subsidiary of Pfizer, and Jubilant Cadista Pharmaceuticals, Inc. as Regular Members of the Association.
Andrew Callos, General Manager, North America, Upjohn (A Division of Pfizer) will serve as Greenstone’s representative on the Board of Directors; and Terry Fullem, President, will serve as Jubilant Cadista’s representative on the Board of Directors.
In addition, AAM is pleased to announce the addition of Operation Smile as an Associate Member.
Generic drugs saved the U.S. health system $293 billion in 2018, according to the Generic Drug Access & Savings in the U.S. report compiled by IQVIA on behalf of AAM.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.